Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer crawled date : 2021 - 12 - 13 save search
Adaptive Biotechnologies Announces New Data Demonstrating the Benefit of Serial MRD Testing with the clonoSEQ® Assay in Patients with Blood Cancers at the 63rd ASH Annual Meeting
Published: 2021-12-13 (Crawled : 21:00) - globenewswire.com
ADPT | $2.595 0.58% 0.39% 2M
|
Commercial Services
|
| O: -0.71%
H: 3.43%
C: -0.15%
clonoseq blood test cancer biotech iot
Junshi Biosciences and Coherus Announce Positive Interim Overall Survival Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
Published: 2021-12-13 (Crawled : 21:00) - globenewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
CHRS | $2.03 -6.88% -7.39% 720K
|
Health Technology
|
| O: -0.83%
H: 0.0%
C: 0.0%
hoice-01 treatment trial lung cancer positive therapy bioscience results cancer phase 3
Tonix Pharmaceuticals Announces Research Collaboration with Columbia University to Study Recombinant Trefoil Factor 2 (rTFF2)-Based Therapy (TNX-1700) for Gastric and Colorectal Cancers
Published: 2021-12-13 (Crawled : 21:00) - globenewswire.com
TNXP | $0.1587 1.21% 1.2% 950K
|
Health Technology
|
| O: 0.44%
H: 0.0%
C: 0.0%
tnx-1700 als research therapy collaboration cancer colorectal cancer
Galectin Therapeutics Discusses Corporate Transformation, Progress of NAVIGATE Trial and Outlines Strategy for Potential Phase 2 Cancer Immunotherapy Trial at Annual Meeting
Published: 2021-12-13 (Crawled : 21:00) - globenewswire.com
GALT | $3.29 -2.66% -2.74% 160K
|
Health Technology
|
| O: -0.67%
H: 0.0%
C: 0.0%
phase 2 trial therapeutics immunotherapy potential therapy cancer
Largest Study to Date Demonstrates Most Blood Cancer Patients Benefit From a Third Primary Dose of mRNA COVID-19 Vaccine
Published: 2021-12-13 (Crawled : 15:00) - biospace.com/
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -0.41%
H: 0.0%
C: 0.0%
covid-19 blood covid cancer vaccine
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-422 for the Treatment of Prostate Cancer
Published: 2021-12-13 (Crawled : 13:00) - biospace.com/
NUVB | $2.66 -0.75% 0.0% 990K
|
|
| O: -0.11%
H: 0.0%
C: 0.0%
nuv-422 new drug treatment fda clearance prostate cancer application drug fda clearance cancer
Athenex to Host a KOL Webinar Today on CAR-NKT Cell Approach to Cancer and Latest Data at the 63rd ASH Annual Meeting
Published: 2021-12-13 (Crawled : 12:30) - globenewswire.com
ATNX | $0.2031 -7.78% 1.9M
|
Health Technology
|
| O: -3.13%
H: 0.0%
C: 0.0%
test cancer oda
Fred Hutchinson Cancer Research Center, in Partnership with Sutro Biopharma, to Present at ASH 2021
Published: 2021-12-13 (Crawled : 12:00) - sutrobio.com
STRO | $3.47 -6.72% -7.2% 540K
|
Health Technology
|
| O: -1.52%
H: 0.0%
C: 0.0%
partnership biopharma research cancer
Genmab Announces that Janssen has Received Conditional European Marketing Authorization for RYBREVANT® (amivantamab) for Patients with Advanced Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations, after Failure of Platinum-base
Published: 2021-12-13 (Crawled : 09:00) - globenewswire.com
GNMSF | News | $290.34 3.83% 340
|
Health Technology
|
| O: 2.8%
H: 0.02%
C: -4.98%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -0.41%
H: 0.0%
C: 0.0%
GMAB | News | $28.47 -0.32% -0.32% 460K
|
Health Technology
|
| O: -0.08%
H: 0.0%
C: 0.0%
rybrevant europe lung cancer authorization cancer
PharmaMar and Jazz Pharmaceuticals Announce Initiation of Confirmatory Phase 3 Clinical Trial of Zepzelca® (lurbinectedin) for the Treatment of Patients with Relapsed Small Cell Lung Cancer
Published: 2021-12-13 (Crawled : 08:00) - prnewswire.com
JAZZ | $108.38 -1.18% -1.19% 400K
|
Health Technology
|
| O: -1.06%
H: 0.0%
C: 0.0%
zepzelca treatment trial lung cancer cancer phase 3
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.